Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.
Makhija说到这种新的联合疗法可增加复发患者生存期的周数，而药物也较易为病人耐受且仅引起轻微不良反应。
Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.
Makhija说到这种新的联合疗法可增加复发患者生存期的周数，而药物也较易为病人耐受且仅引起轻微不良反应。
应用推荐